

Supplemental Figure S2.




Figure S2. (A) Cell lysates were immunoprecipitated with anti-DOCK2 or anti-FLT3 antibody, and the immunoprecipitated samples were blotted for phosphotyrosine and FLT3. -: no treatment; FL: treatment with FLT3 ligand (10 ng/mL, 10 min); TKI: treatment with sorafenib (25 nM, 1hr). (B) Lysates of an equal number of Molm 14 cells were immunoprecipitated with anti-FLT3 antibody. -: no treatment; MG132: treatment with 5 μ M MG132 for 1 hr prior to cell lysis; DSP: treatment with 1 mM DSP for 1.5 hr prior to cell lysis. (C) Lysates of TF-1-FLT3/ITD (ITD) and TF-1-FLT3/WT (WT) cells were immunoprecipitated with anti-DOCK2 antibodies and the immunoprecipitated samples were blotted for DOCK2, P-Tyr and FLT3. (D) Lysates of SEM K2 cells were immunoprecipitated with normal mouse serum or anti-DOCK2 antibodies, and the immunoprecipitated samples were blotted for DOCK2, P-FLT3(Y589/591) and FLT3.